Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Apr;55(8):1070-1071.
doi: 10.1111/apt.16896.

Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply

Christian P Selinger  1 , Marco Vincenzo Lenti  1   2 , Annalisa De Silvestri  3
Affiliations
Comment

Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply

Christian P Selinger et al. Aliment Pharmacol Ther. 2022 Apr.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Adomi M, Ray A. Letter: potential selection bias in real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn’s disease. Aliment Pharmacol Ther. 2022;55:1069.
    1. Lenti MV, Dolby V, Clark T, Hall V, Tattersall S, Fairhurst F, et al. A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn’s disease. The cross Pennine study II. Aliment Pharmacol Ther. 2022;55:856-866.
    1. Irving PM, Sands BE, Hoops T, Izanec JL, Gao LL, Gasink C, et al. OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in moderate-to-severe Crohn’s disease: the SEAVUE study. J Crohn’s Colitis. 2021;15:S001-2.
    1. Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763-74.
    1. Manlay L, Boschetti G, Pereira B, Flourié B, Dapoigny M, Reymond M, et al. Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor therapy. Aliment Pharmacol Ther. 2021;53:1289-1299.

MeSH terms

LinkOut - more resources